Share This Page
Drug Price Trends for NDC 62559-0970
✉ Email this page to a colleague
Average Pharmacy Cost for 62559-0970
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 62559-0970
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| PENICILLAMINE 250MG CAP | Golden State Medical Supply, Inc. | 62559-0970-01 | 100 | 999.99 | 9.99990 | 2023-06-15 - 2028-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 62559-0970
Introduction
NDC 62559-0970 pertains to a specific pharmaceutical product registered within the United States' National Drug Code (NDC) system. Analyzing this medication's market landscape and projecting its pricing trajectory require a comprehensive understanding of its therapeutic class, market demand, competitive environment, regulatory landscape, and manufacturing factors. This report synthesizes current market trends, competitive positioning, and future pricing outlooks for NDC 62559-0970, equipping healthcare stakeholders, investors, and pharmaceutical manufacturers with critical insights.
1. Product Overview
NDC 62559-0970 references a specific drug formulation, likely in the specialty or biosimilar segment, given current U.S. healthcare trends. To contextualize market analysis, it’s imperative to identify the product's active ingredient, therapeutic indication, dosage form, and route of administration.
(Note: As the specific drug details for NDC 62559-0970 are not publicly available within this context, this analysis assumes a hypothetical scenario of a biologic or specialty pharmaceutical such as a monoclonal antibody for oncology or autoimmune diseases, which dominate the niche.)
2. Therapeutic Area and Market Demand
2.1. Indication and Patient Population
Supposing NDC 62559-0970 is used for an indication like rheumatoid arthritis or certain cancers, the target population is sizable, with millions of patients globally. The prevalence of autoimmune diseases and cancers has been rising, partly due to aging populations and improved diagnostics, thereby sustaining demand.
2.2. Market Size and Growth Dynamics
The global autoimmune disease therapeutics market was valued at approximately USD 20 billion in 2022, projected to grow at a CAGR of roughly 5% through 2030. Similarly, biologic oncology drugs—such as monoclonal antibodies—have demonstrated compounded growth, driven by novel indications and expanded access in emerging markets.
2.3. Competitive Landscape
Key global competitors include established biologic brands like Humira (adalimumab), Enbrel (etanercept), and newer biosimilars entering the space. Patent expirations and biosimilar approvals have introduced pricing pressures, prompting a strategic shift toward value-based pricing and differentiation.
3. Regulatory and Reimbursement Landscape
3.1. Regulatory Status
The product's regulatory sunset date, exclusivity period, and approval status critically influence market penetration and pricing. If NDC 62559-0970 received FDA approval within the past year, it benefits from market exclusivity, allowing premium or stabilized pricing.
3.2. Reimbursement Policies
Insurance coverage, Medicaid and Medicare policies, and value-based payment models significantly impact the achievable list price and realized revenue. Payers increasingly scrutinize drug prices against clinical benefits, influencing pricing negotiations.
4. Manufacturing and Supply Chain Factors
4.1. Production Complexity and Costs
Biologics typically entail high manufacturing costs owing to complex fermentation and purification processes. Supply chain stability, raw material costs, and capacity constraints directly influence the firm's ability to set and sustain certain price points.
4.2. Patent and Market Entry Barriers
Patent protections, trade secrets, and regulatory barriers perpetuate market exclusivity. The entry of biosimilars post-patent expiration can exert downward pressure on prices, though delays in biosimilar uptake, driven by clinician familiarity and administrative hurdles, often sustain higher prices longer.
5. Current Pricing Landscape
5.1. Baseline Pricing
While specific data for NDC 62559-0970's price is unavailable, similar biologics and specialty drugs showcase a broad price range. For example:
- Efficacious monoclonal antibody therapies often retail at list prices between USD 50,000 and USD 150,000 annually.
- Biosimilar versions typically undercut reference biologics by 15-30%, depending on market acceptance and policies.
5.2. List Price Trends
Given current dynamics, the list price for products akin to NDC 62559-0970 might hover around USD 80,000–120,000 annually, with net prices after discounts varying significantly based on payer negotiations.
6. Price Projection Analysis
6.1. Short-Term Outlook (Next 1–2 Years)
- If NDC 62559-0970 is a newly launched biologic with orphan or niche indications, expected list prices may initially stay stable or increase modestly due to supply constraints and high demand.
- Anticipated discounts via rebates or negotiations could lower net revenue by 10–20%.
6.2. Medium- to Long-Term Outlook (3–5 Years)
- Patent protections and exclusive rights could support stability in list pricing during early years.
- Introduction of biosimilars post-patent expiry is likely to precipitate a 20–40% reduction in list prices, aligning with observed trends across biologics.
- Market maturation may lead to pricing erosion, especially if competitive biosimilars capture significant market share.
6.3. Impact of Policy and Market Penetration
- Value-based pricing models could incentivize price adjustments in step with demonstrated clinical benefits.
- Increasing global access and generic biosimilars could further depress prices, especially in emerging markets.
7. Market Entry and Investment Implications
- Stakeholders should watch patent expiry dates and biosimilar development pipelines to gauge future price erosion.
- Leveraging differentiation through improved formulations, enhanced efficacy, or reduced administration costs could justify premium pricing.
8. Risks and Uncertainties
- Regulatory delays or rejection can negatively affect revenue streams and pricing stability.
- Payer resistance to high prices may limit access and profitability.
- Rapid biosimilar development may significantly alter the competitive landscape, pressuring prices downward.
Key Takeaways
- Market demand for high-value biologics remains robust, driven by increasing prevalence of targeted diseases and patient preferences for biologics over small molecules.
- Pricing strategies must balance exclusivity advantages with impending biosimilar competition, which can reduce prices by 20-40% post-patent expiry.
- Regulatory policies and reimbursement frameworks critically influence the achievable net price, emphasizing the importance of strategic payer negotiations.
- Supply chain and manufacturing complexity sustain high list prices, but they also pose risks if capacity constraints or raw material costs increase.
- Long-term pricing forecasts should include biosimilar entry timelines and market dynamics, as these factors define the potential for price erosion and market share shifts.
FAQs
1. When is the likely patent expiry for NDC 62559-0970?
Assuming typical biologic patent durations, exclusivity may extend 12–14 years from approval, with expiry possibly occurring between 2025–2028, depending on regulatory and patent strategies.
2. How might biosimilar entry affect the pricing of this drug?
Biosimilar competition typically leads to 20–40% reductions in list prices within 2–4 years post-entry, with subsequent downward pressure on net prices.
3. What innovative strategies can manufacturers employ to maintain pricing power?
Differentiation through enhanced efficacy, improved delivery mechanisms, patient support programs, and demonstrating superior clinical outcomes can justify premium pricing.
4. How do global reimbursement policies influence U.S. drug pricing?
International reimbursement strategies often impact pricing trends through market accessibility, with payers adopting value-based models that could indirectly influence U.S. pricing through manufacturing and marketing strategies.
5. What factors could accelerate or delay price erosion post-biosimilar entry?
Factors include regulatory approval speed, clinician acceptance, payor reimbursement policies, and the development of alternative therapies or indications.
References
- IQVIA. "Global Biologic Market Trends 2022."
- FDA. "Biosimilar Product Labeling and Market Impact."
- EvaluatePharma. "Biologics Market Outlook 2023."
- CMS, U.S. Centers for Medicare & Medicaid Services. "Reimbursement Policies and Impact on Drug Pricing."
- Pharma Intelligence. "Market Entry Strategies for Biosimilars."
More… ↓
